SCHEMBL10706361

SCHEMBL10706361

CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 5/20 0.56
▸ LMNA P02545 4/20 0.56
▸ NR3C1 P04150 4/20 0.56
▸ PGR P06401 3/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ NPSR1 Q6W5P4 2/20 0.56
▸ MAPT P10636 2/20 0.56
▸ HPGD P15428 1/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ MLNR O43193 1/20 0.56
▸ NR1I2 O75469 1/20 0.56
▸ ADORA3 P0DMS8 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ SLC6A3 Q01959 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ PDE4D Q08499 1/20 0.56
▸ PDE3A Q14432 1/20 0.56
▸ HIF1A Q16665 1/20 0.56
▸ AR P10275 3/20 0.50
▸ NR3C2 P08235 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10703743 0.98 NR3C1 (0.53) CYP3A4LMNANR3C1PGRSMN1; SMN2
SCHEMBL10705558 0.94 NR3C1 (0.52) CYP3A4LMNANR3C1PGRSMN1; SMN2
SCHEMBL11799760 0.91 CYP3A4 (0.55) CYP3A4LMNANR3C1PGRSMN1; SMN2
SCHEMBL11800122 0.91 CYP3A4 (0.55) CYP3A4LMNANR3C1PGRSMN1; SMN2
SCHEMBL11799756 0.91 CYP3A4 (0.55) CYP3A4LMNANR3C1PGRSMN1; SMN2
SCHEMBL11800114 0.91 CYP3A4 (0.55) CYP3A4LMNANR3C1PGRSMN1; SMN2
SCHEMBL10703144 0.90 NR3C1 (0.54) CYP3A4LMNANR3C1PGRSMN1; SMN2
SCHEMBL10704998 0.86 NR3C1 (0.65) CYP3A4LMNANR3C1PGRSMN1; SMN2
SCHEMBL10705476 0.85 NR3C1 (0.69) CYP3A4LMNANR3C1PGRSMN1; SMN2
SCHEMBL10704393 0.83 NR3C1 (0.66) CYP3A4LMNANR3C1PGRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0153270-B1 1-ALPHA, 2-ALPHA-METHYLENE-6-METHYLENE AND 6-ALPHA-METHYL PREGNENES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING AKTIENGESELLSCHAFT (DE) 1988-07-27 — — EP claimed
EP-0153270-A2 1-Alpha, 2-alpha-methylene-6-methylene and 6-alpha-methyl pregnenes, process for their preparation and pharmaceutical compositions containing them SCHERING AKTIENGESELLSCHAFT (DE) 1985-08-28 — — EP claimed
EP-0153270-B1 1-ALPHA, 2-ALPHA-METHYLENE-6-METHYLENE AND 6-ALPHA-METHYL PREGNENES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING AKTIENGESELLSCHAFT (DE) 1988-07-27 — — EP disclosed
US-4670427-A ANTIANDROGENS SCHERING AKTIENGESELLSCHAFT (DE) 1987-06-02 — — US disclosed
EP-0153270-A2 1-Alpha, 2-alpha-methylene-6-methylene and 6-alpha-methyl pregnenes, process for their preparation and pharmaceutical compositions containing them SCHERING AKTIENGESELLSCHAFT (DE) 1985-08-28 — — EP disclosed
Send feedback